Excellergy launched with a $70 million Series A led by Samsara Biocapital to advance effector cell response inhibitors (ECRIs), a new therapeutic class designed to rapidly disarm IgE‑driven allergic responses. The company says ECRIs act across multiple pathways to remove IgE bound to FceRI without activating mast cells or basophils. Excellergy positions its approach as a category reset rather than incremental change. The financing will push preclinical programs toward first‑in‑human studies planned for early next year and signals investor appetite for novel allergy therapeutics that could compete with established anti‑IgE biologics.